Linee Guida Italiane HIV 2012.pdf - SIMaST

26. Grund, B., et al., Continuous antiretroviral therapy decreases bone mineral density. AIDS, 2009. 23(12): p.1519-29.27. Negredo, E., et al., Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospectivestudy comparing autologous fat and synthetic substances. AIDS Patient Care STDS, 2006. 20(12): p. 829-37.28. Bischoff-Ferrari, H.A., et al., Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiplehealth outcomes. Am J Clin Nutr, 2006. 84(1): p. 18-28.29. Mueller, N.J., et al., High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naiveand successfully treated Swiss HIV patients. AIDS.30. Cozzolino, M., et al., HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D.AIDS, 2003. 17(4): p. 513-20.31. Paccou, J., et al., Bone loss in patients with HIV infection. Joint Bone Spine, 2009. 76(6): p. 637-41.32. Borderi, M., et al., Metabolic bone disease in HIV infection. AIDS, 2009. 23(11): p. 1297-310.33. Labarga, P., et al., Kidney tubular abnormalities in the absence of impaired glomerular function in HIVpatients treated with tenofovir. AIDS, 2009. 23(6): p. 689-96.34. Worm, S.W., et al., Risk of myocardial infarction in patients with HIV infection exposed to specific individualantiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs(D:A:D) study. J Infect Dis. 201(3): p. 318-30.35. Hughes, C.A., et al., New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, andresistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert OpinPharmacother, 2009. 10(15): p. 2445-66.36. Chowers, M., et al., Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients:systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis, 2010. 29(7): p. 779-86.37. Mallal, S., et al., HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med, 2008. 358(6): p. 568-79.38. Saag, M., et al., High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologicallyconfirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis, 2008. 46(7): p. 1111-8.39. Escaut, L., et al., Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS, 1999.13(11): p. 1419-20.40. Malan, D.R., et al., Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highlyactive antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr, 2008.47(2): p. 161-7.41. Molina, J.M., et al., Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each incombination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients:48 week efficacy and safety results of the CASTLE study. Lancet, 2008. 372(9639): p. 646-55.42. Rodriguez-Novoa, S., et al., Genetic factors influencing atazanavir plasma concentrations and the risk ofsevere hyperbilirubinemia. AIDS, 2007. 21(1): p. 41-6.43. Munoz-Moreno, J.A., et al., Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, andmanagement. A neurobehavioral review. AIDS Rev, 2009. 11(2): p. 103-9.44. Haas, D.W., et al., Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDSClinical Trials Group study. AIDS, 2004. 18(18): p. 2391-400.45. El-Sadr, W.M., et al., Effects of HIV disease on lipid, glucose and insulin levels: results from a largeantiretroviral-naive cohort. HIV Med, 2005. 6(2): p. 114-21.46. Law, M.G., et al., The use of the Framingham equation to predict myocardial infarctions in HIV-infectedpatients: comparison with observed events in the D:A:D Study. HIV Med, 2006. 7(4): p. 218-30.47. Rossi, R., et al., The role of the Framingham risk score to predict the presence of subclinical coronaryatherosclerosis in patients with HIV infection. J Acquir Immune Defic Syndr, 2009. 52(2): p. 303-4.48. Greenland, P., et al., ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoringby computed tomography in global cardiovascular risk assessment and in evaluation of patients with chestpain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force(ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron BeamComputed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging andPrevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol, 2007. 49(3): p. 378-402.49. De Socio, G.V., et al., Relations between cardiovascular risk estimates and subclinical atherosclerosis innaive HIV patients: results from the HERMES study. Int J STD AIDS. 21(4): p. 267-272.